Gregory Knopf, MD
Family Medicine · Troutdale, ORNPI 1508837378
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 72.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $6,458 and has fallen 99.6% since, to $28 in 2021. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $49.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Astellas Pharma US Inc$321
- GSK$210
- Boehringer Ingelheim$166
- AbbVie$134
- Novo Nordisk$123
- plus $1K from 22 others
What the payments were for
- Consulting fees$3,30046%
- Travel & lodging$1,39619%
- Food & beverage$2,26332%
- Education$2043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $5,166 |
| Astellas Pharma US Inc | 8 | $321 |
| GSK | 17 | $210 |
| Boehringer Ingelheim | 8 | $166 |
| AbbVie | 10 | $134 |
| Novo Nordisk | 8 | $123 |
| Amgen | 5 | $101 |
| Merck | 8 | $98 |
| Johnson & Johnson | 6 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| AstraZeneca | 6 | $76 |
| Novartis | 4 | $74 |
| Lilly USA, LLC | 5 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $56 |
| Antares Pharma, Inc. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Circassia Inc. | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $6 |
How this compares
$7,163 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $92,810 |
| RexultiBrexpiprazole | 30 | $55,491 |
| Wellbutrin XlBupropion Hcl | 13 | $52,966 |
| OzempicSemaglutide | 42 | $52,641 |
| JardianceEmpagliflozin | 28 | $31,290 |
| XareltoRivaroxaban | 22 | $30,400 |
| JanuviaSitagliptin Phosphate | 20 | $26,789 |
| TradjentaLinagliptin | 21 | $22,363 |
| MyrbetriqMirabegron | 12 | $16,831 |
| FarxigaDapagliflozin Propanediol | 15 | $12,596 |
| LivaloPitavastatin Calcium | 15 | $7,618 |
| Testosterone | 22 | $6,189 |
| Irbesartan | 296 | $5,551 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 78 | $5,317 |
| Levothyroxine Sodium | 473 | $4,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,166 | $92,81076 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $41 | $55,49130 claims |
| Boehringer IngelheimJardiance, Tradjenta | $166 | $53,65349 claims |
| Novo NordiskOzempic | $123 | $52,64142 claims |
| Johnson & JohnsonXarelto | $97 | $30,40022 claims |
| MerckJanuvia | $98 | $26,78920 claims |
| Astellas Pharma US IncMyrbetriq | $321 | $16,83112 claims |
| AstraZenecaFarxiga | $76 | $12,59615 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $35 | $7,61815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Troutdale
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
- Carl EricksonMilwaukie$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.